Half Year Report 2019
Orion published Half Year Report 2019 on Wednesday 17 July 2019.
Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.
8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.
The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
|9/2/2019||135,000 Orion Corporation A shares converted into B shares|
|7/17/2019||Orion Group Half-Year Financial Report January–June 2019|
|7/17/2019||Orion Corporation's financial reporting and Annual General Meeting in 2020|
|6/19/2019||1,767 Orion Corporation A shares converted into B shares|
|10/7/2019||Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019|
|9/10/2019||Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers|
|8/7/2019||Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone|
|7/31/2019||U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.